Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $11.67

by · The Cerbat Gem

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $14.3333.

EPRX has been the topic of several analyst reports. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th.

Read Our Latest Stock Report on Eupraxia Pharmaceuticals

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter worth $61,000. TCI Wealth Advisors Inc. bought a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at about $65,000. Integrated Wealth Concepts LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $71,000. Bank of America Corp DE lifted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Trading Down 0.2%

Shares of Eupraxia Pharmaceuticals stock opened at $8.75 on Thursday. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $8.89. The business’s 50 day simple moving average is $6.86 and its 200-day simple moving average is $6.00. The stock has a market capitalization of $314.65 million, a price-to-earnings ratio of -10.06 and a beta of 1.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. Sell-side analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

Further Reading